Background: Lack of Awareness for Cognitive Decline (ACD) has been described at the preclinical and 16 prodromal stages of Alzheimer's disease (AD). In this study, we introduced a meta-memory ratio (MMR), and 17 explored how it is associated with neuroimaging AD biomarkers in asymptomatic individuals at risk for AD.
Introduction

27
In Alzheimer's disease (AD), the first lesions, and in particular the aggregation of brain amyloid, appear 28 several decades before the clinical diagnosis of dementia [1] [2] [3] . Numerous studies have also shown that the 29 accumulation of these lesions is accompanied by a subtle decline in several cognitive domains, including have shown that impairment in ACD could occur before the clinical stage. Using the patient-informant 48 discrepancy in asymptomatic at risks for AD subjects, we found that a higher level of AD biomarkers 49 (i.e. amyloidosis and hypometabolism) in CN individuals was related to a low ACD [25] . Several other studies 50 using the subjective-objective performance discrepancy approach, showed low awareness of decline, both in 51 asymptomatic individuals at risk for AD [26] and in individuals with MCI [24, [27] [28] [29] [30] [31] . Furthermore, Munro 52 and colleagues [30] demonstrated that the presence of anosognosia could predict future conversion from MCI 53 to clinical AD. There exists consistent evidence that anosognosia would be associated to mainly frontal but 54 also temporoparietal dysfunctions, notably in the regions involved in self-referenced treatment and memory 55 [26, 28] , as well as to a disconnection between these same areas [27] . Similarly, anosognosia could be linked to 56 the amount of cerebral amyloidosis in individuals with MCI [31, 32] . 57 For each cohort, we used only baseline data. Our final sample therefore consisted of 448 CN participants 90 with SCD. As objective measure of cognitive functioning, we have chosen to focus on the domain of memory. Indeed, 94 recent research tends to show that the subtle decline in memory occurring in preclinical AD would be among 95 the earliest to evidence of a transition to a subsequent prodromal AD [1, [5] [6] [7] [8] . 96 Details of the neuropsychological examination proposed in the INSIGHT-PreAD cohort were previously 97 described [34] . In this study, we selected three episodic memory scores: Monitor questionnaire (HABCM). In this questionnaire, subjects rate the frequency of occurrence of cognitive 108 disturbances during the last two weeks (i.e. from 0,'not at all (0-1 day)', to 3,'almost daily (12-14 days)').
109
The HABC-M cognitive scale consists of 6 items, the majority of which are related to the memory domain.
110
The total score ranges from 0 to 18.
111
For the ADNI participants, we used the Everyday Cognition questionnaire score (ECog). This questionnaire 112 asks the participant to compare his/her current ability to perform everyday tasks to that of ten years ago.
113
The estimate is based on a 5-point scale, with higher scores indicating a better self-perceived functional 114 decline. The items focus on memory, language and executive functioning. 
The Meta-Memory Ratio 116
We based our measure of awareness on the model of the "anosognosia index" initially proposed by Dalla 117 Barba and collaborators [35] . This procedure consists in measuring a gap between the subjective complaint 118 and an objective performance. To compute the score, the same procedure was implemented independently in 119 each cohort (Figure 1 ). 120 4 First, since the two samples had different demographic distributions and these variables can be associated 121 with the scores of interest, we started by removing their impact on the scores. Each score of interest 122 (i.e. memory performances and complaint questionnaires) was integrated into a generalized linear model 123 (GLM), as a dependent variable. These models included demographic variables (i.e. age, gender and socio-124 cultural level) as covariates, to correct for their potential effects. For each measure, the type of model used 125 was selected according to the distribution of each score (i.e. linear regressions for ROCF, ECog, immediate 126 RAVLT, and ADAS-Q4; logistics for FCSRT intrusions and perseverations; and binomial for the other 127 measures mentioned). Subsequently, we extracted the model residuals to obtain the performance without 128 these effects.
129
Secondly, we have centered and reduced all the residuals in order to make them comparable (i.e. z-score 130 transformation).
131
Thirdly, we computed a composite score by averaging all memory scores collected for each subject. In this 132 way, we had two values. The first one represented an objective measure of memory function. The higher this 133 score, the better the memory performance at testing. The second one represented a subjective measure of 134 memory. The higher this score, the higher the memory complaint.
135
Finally, we added the two scores of subjective and objective performance. By construction, an MMR close 136 to 0 corresponds to a good match between subjective and objective performance (i.e. accurate ACD). The 137 higher the MMR is, the more it corresponds to an SCD (i.e. important complaint with correct performance).
138
On the contrary, the lower it is, the more the ACD is low (i.e. lower complaint associated with a poorer 139 performance; Figure 1 ). To make the two cohorts neuroimaging features comparable, we normalized the SUVr using the respective 150 amyloid positivity threshold of each cohort. To do so, we divided the SUVr of each participant by the 151 positivity threshold, i.e. 0.79 for the INSIGHT-PreAD cohort and 1.11 for ADNI. Thus, any normalized SUVr 152 5 above 1 could be considered significantly pathological (i.e. amyloid-positive patients).
153
FDG-PET Imaging 154
For each of our cohorts, we calculated a mean metabolism index using Fluorodeoxyglucose Positon Emission 155 Tomography (FDG-PET) by averaging the regions of interest (ROIs) of AD, namely the posterior cingulate 156 cortex, inferior parietal lobule, precuneus and inferior temporal gyrus [37] . Then, since the FDG-PET did not 157 have an established cut-off, we normalized this meta-ROI using a centered-reduced method (i.e. intra-cohort 158 z-score transformation). As for amyloid PET imaging, details are available in supplementary materials. The different scores of interest (MMR, complaint and memory) and demographic variables were compared 161 between the two cohorts using Welch's t-tests for the numerical variables, and a Chi 2 -test for the gender 162 variable.
163
MMR scores were normally distributed. In order to evaluate the influence of AD biomarkers on awareness, 164 we computed a linear regression model with the MMR as dependent variable. To account for the specific 165 effect of each biomarker, amyloidosis (AV45-PET) and metabolism (FDG-PET) were both included in the 166 model. We also included interactions between the "cohort" effect and biomarkers to determine whether the 167 effect of biomarkers varied across cohorts. Finally, we adjusted the results including demographic (i.e. age, 168 gender and education) and the cohort variables as covariates.
169
Looking at the scatterplot between MMR and AV45-SUVr, we identified a non-linear effect of amyloid on 170 the MMR, a quadratic effect of amyloid was added to the models. The main effects and interactions were 171 tested via the likelihood ratio test type II. Normality of residuals and heteroskedasticity were checked visually.
172
Cook's distances and hat values were computed to investigate potential influencers and outliers.
173
Statistical analyses were performed using R 3.5.2 (https://www.R-project.org/). An R package was 174 developed for the calculation of MMR in various cohorts (https://github.com/GagGeo/MMAD). (Table 1) . 180 Secondly, with regard to AD biomarkers, ADNI subjects had a significantly higher amyloid load than 181 INSIGHT subjects (1.0 ± 0.2 vs 0.9 ± 0.2, p <0.001). Overall, these imaging variables appeared to be 182 normally distributed across the two cohorts. The model ( Figure 3 ) showed a trend in the effect of the FDG-PET meta-ROI on the MMR score (p 185 = 0.61) that increased with increasing metabolism. Regarding the AV45 PET value, the model showed a 186 significant combined (linear and squared) effect on the MMR score (p < 0.05). In this quadratic effect, an 187 inflection point is observed at a normalized SUVr value of 1.08.
188
Our model (Table 2) 
Discussion
192
In this study, we had two distinct objectives. On the one hand, we aimed to determine the chronology of 193 variations in awareness in the early stages of AD. On the other hand, we aimed to develop a new method to 194 assess the ACD that can be applied in several SCD cohorts, in order to obtain more generalizable results. 195 We have thus developed the MMR, which provides a continuous measurement of the awareness of one's own 196 memory performance. To assess its applicability on a trans-cohort perspective, we implemented the MMR in 197 two separate samples, the INSIGHT-PreAD and ADNI cohorts.
198
Regarding amyloidosis, normalized using cohort positivity thresholds. This method is less accurate than 199 the Centiloid scale [38] . However, Habert and colleagues [36] showed a strong correlation between the Avid 200 (used in ADNI) and CATI (used in INSIGHT-PreAD) methods (r = 0.9). We thus considered our SUVr 201 normalization as an acceptable approximation, with improved processing time and simplicity.
202
The regression between MMR and AD biomarkers (i.e. amyloidosis and brain metabolism) showed a significant 203 quadratic effect of amyloidosis: the MMR scores increased, indicating a complaint without objective decline, 204 with increasing amyloid load, up to a certain threshold, above which the increase in amyloid load was 205 associated with a lower MMR score, indicating a decline in the ACD. This is consistent with previous 206 studies indicating that both SCD and low ACD could be associated with a greater risk of AD pathology 207 [10-14,25]. These findings may appear contradictory. However, they can be understood as two successive 208 chronological periods. Vannini and colleagues [32] proposed that, at the preclinical stage, a hyper-vigilance 209 towards otherwise undetected cognitive difficulties (i.e. hypernosognosia, SCD) would precede subsequent low 210 ACD. Our results are thus in line with this chronological model. Individuals with SCD would be at an early 211 stage of the disease, before the decrease in ACD. Interestingly, with the inflection point at 1.08, it seems that 212 the complaint progresses into a low and decreasing ACD when the participants become amyloid positive.
213
Previous studies had already shown a link between amyloidosis and anosognosia in MCI populations [31, 32] . The present study demonstrated this relationship in CN individuals.
215
These results have strong implications in both research and clinical practice. Indeed, some consider that 216 the appearance and aggravation of a complaint could be used as a marker of risk of having AD lesions [10] [11] [12] [13] [14] . 217 However, our study showed that the accumulation of amyloidosis initially leads to increasing complaints, 218 eventually turning into poor awareness. Thus, the presence of persistent cognitive complaints should not 219 be considered as indicative of AD, but due to other etiologies [20, 21] . Even in the presence of amyloid 220 accumulation, cognitive complaints should be considered as a minor risk for AD. Indeed, some studies showed 221 an increase in amyloid burden with advancing age [39], regardless of whether or not there is a subsequent 222 conversion to AD. Demonstrating that the decrease in awareness takes place beyond the amyloid-positivity 223 threshold, it seems that low awareness, rather than complaints, should be taken as marker of AD. Taken 224 together, our results seem to validate the chronological models mentioned above, which assumes an increase 225 and then a decrease in the ACD during the evolution towards the diagnosis of AD [32, 40] .
226
In our study, a trend emerged but there was no significant effect of metabolism on MMR (i.e. higher 227 metabolism resulting in a higher MMR score). There are several possible reasons. To begin with, since 228 amyloid is the first biomarker to accumulate [41] , hypometabolism only occurs later. Demonstrating a 229 relationship between amyloidosis but not neurodegeneration (represented here by hypometabolism), these 230 data could mean that defects in consciousness of the disorders may be sensitive earlier than variations in 231 brain metabolism.
232
In addition, we analyzed mean metabolic indices in AD ROIs, selected from previous research for their 233 sensitivity and specificity in clinical AD [37] . However, deficits in ACD could not be associated with the same 234 brain regions. Indeed, awareness has often been associated with cortical midline structures [27, 28, 32] , as well 235 as right prefrontal regions [42, 43] . For instance, a recent study conducted as part of the INSIGHT-PreAD 236 study found that low awareness was related to lower brain metabolism in a fronto-temporo-parietal network 237 [25].This network does not overlap with that considered in this study. Traditionally, AD symptoms have been 238 attributed to tauopathy [44] . However, at this preclinical stage, tauopathy is mainly localized in the mesial 239 temporal regions [45] , and it is probably subtle given the absence of significant memory deficits. Amyloidosis, 240 on the other hand, begins to accumulate upstream [3, 41, 46] notably in prefrontal regions [47] which seems to 241 be related to awareness [25, 42, 43] . This may explain the stronger relationship between MMR and amyloid 242 load than with metabolism. Nevertheless, further longitudinal studies are needed to conclude on the neural 243 correlates of the decline in ACD.
244
In this study, we compared objective performance with the subjective perception of participants. As 245 explained above, other methods exist to evaluate ACD [22, 23] . In a previous study with asymptomatic 246 individuals, we had shown that a discrepancy between the subject's and informant's perceptions resulted in 247 8 higher levels of biomarker accumulation [25] . Few studies have attempted to compare awareness measures 248 [24] , and the question arises as to what would be the best tool to measure a weakening of the ACD. It would 249 be interesting to directly compare the MMR methodology to existing assessment methods.
250
There are some limitations to our study. First, despite our efforts to make the measures comparable 251 with each other, the scores used to compute the MMR are not exactly the same in the two cohort, and 252 they might involve slightly different cognitive processes. Moreover, the cohorts varied on two of the three The MMR has demonstrated its applicability in a trans-cohort setting. Using this methodology, we 262 observed a quadratic relationship between ACD and cerebral amyloidosis. In particular, the more cerebral Requests for access to the original data should be addressed to the study sponsors.
294
The ADNI data are available at http://adni.loni.usc.edu.
295
The INSIGHT-PreAD study data are available at https://www.gaaindata.org/partner/ Access rights are subject to the submission of a project. 
